Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Other hematologic neoplasm 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myeloid, Acute 5Pathologic Complete Response 2Myelodysplastic Syndromes 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Leukemia 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 4sargramostim 3Psychiatric Rehabilitation 3Paclitaxel 3Flow Cytometry 3trametinib 2pertuzumab 2pembrolizumab 2dabrafenib 2Trastuzumab 2Specimen Handling 2Palliative Care 2Methylprednisolone 2Melphalan 2Magnetic Resonance Spectroscopy 2Immunologic Techniques 2Filgrastim 2Biopsy 2Azacitidine 2Analgesia 2Amifostine 2Alemtuzumab 2varlilumab 1ulixertinib 1trastuzumab biosimilar HLX02 1tanespimycin 1stenoparib 1sapanisertib 1ruxolitinib 1rucaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Monatide (IMS 3015) × Other hematologic neoplasm × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡